Average Co-Inventor Count = 5.93
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Sanofi (33 from 1,451 patents)
2. Sanofi-a Ventis Deutschland Gmbh (17 from 1,827 patents)
3. Sanofi-aventis (5 from 389 patents)
4. Hoechst Aktiengesellschaft (4 from 6,662 patents)
5. The General Hospital Corporation (3 from 2,882 patents)
6. Aventis Pharma Deutschland, Gmbh (2 from 330 patents)
7. The Brigham and Women's Hospital, Inc. (1 from 1,370 patents)
62 patents:
1. 10758592 - Exendin-4 derivatives as dual GLP1/glucagon agonists
2. 10253079 - Functionalized Exendin-4 derivatives
3. 9932381 - Exendin-4 derivatives as selective glucagon receptor agonists
4. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
5. 9775904 - Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
6. 9771406 - Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
7. 9758561 - Dual GLP-1/glucagon receptor agonists derived from exendin-4
8. 9751926 - Dual GLP-1/GIP receptor agonists
9. 9750788 - Non-acylated exendin-4 peptide analogues
10. 9745360 - Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
11. 9694053 - Dual GLP-1/glucagon receptor agonists
12. 9670261 - Functionalized exendin-4 derivatives
13. 9365632 - Exendin-4 derivatives as dual GLP1/glucagon agonists
14. 9181305 - Exendin-4 peptide analogues
15. 8859494 - Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament